Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells

EMT, CTCs and CSCs in tumor relapse and drug-resistance

(2015) Abhisek Mitra et al.   Oncotarget

Tumor-Initiating Cells and FZD8 Play a Major Role in Drug Resistance in Triple-Negative Breast Cancer

(2013) S. Yin et al.   MOLECULAR CANCER THERAPEUTICS

Disparities in Breast Cancer Treatment and Outcomes: Biological, Social, and Health System Determinants and Opportunities for Research

(2013) S. B. Wheeler et al.   ONCOLOGIST

Mammosphere Formation in Breast Carcinoma Cell Lines Depends upon Expression of E-cadherin

(2013) Juan Manuel Iglesias et al.   PLoS One

Cadherins in collective cell migration of mesenchymal cells

(2012) Eric Theveneau et al.   CURRENT OPINION IN CELL BIOLOGY

Early events in cell adhesion and polarity during epithelial-mesenchymal transition

(2012) R. Y.-J. Huang et al.   JOURNAL OF CELL SCIENCE

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

(2012) Dai Horiuchi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Triple-negative breast cancers: an updated review on treatment options

(2011) K. B. Reddy   Current Oncology

Heterogeneity in breast cancer

(2011) Kornelia Polyak   JOURNAL OF CLINICAL INVESTIGATION

MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors

(2011) Aatur D Singhi et al.   MODERN PATHOLOGY

Wnt Proteins Are Self-Renewal Factors for Mammary Stem Cells and Promote Their Long-Term Expansion in Culture

(2010) Yi Arial Zeng et al.   Cell Stem Cell

Targeting Breast Cancer Stem Cells

(2010) Suling Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1

(2010) E Sánchez-Tilló et al.   ONCOGENE

Directed Therapy of Subtypes of Triple-Negative Breast Cancer

(2010) L. A. Carey   ONCOLOGIST

Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase

(2010) D. Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A pathway-based classification of human breast cancer

(2010) M. L. Gatza et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

EMT, the cytoskeleton, and cancer cell invasion

(2009) Mahmut Yilmaz et al.   CANCER AND METASTASIS REVIEWS

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery

(2009) Bin-Bing S. Zhou et al.   NATURE REVIEWS DRUG DISCOVERY

Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the “Basal” Breast Cancer Subgroup

(2009) M. Chehani Alles et al.   PLoS One

A Core MYC Gene Expression Signature Is Prominent in Basal-Like Breast Cancer but Only Partially Overlaps the Core Serum Response

(2009) Sanjay Chandriani et al.   PLoS One

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells

(2009) J. J. Molenaar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Why Myc? An Unexpected Ingredient in the Stem Cell Cocktail

(2008) Paul S. Knoepfler   Cell Stem Cell

c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells

(2008) Jialiang Wang et al.   PLoS One